Kymera Therapeutics

KYMR · NASDAQ

$113.46+$5.39 (+4.99%)TodayMarket closed · Oct 20, 6:27 PM ET

Prev close $108.07

Latest news

Press releaseOct 12, 9:30 AM ETPRNewswire
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Kymera Therapeutics, Inc. (NASDAQ: KYMR)
Press releaseSep 30, 8:59 AM ETPRNewswire
Kuehn Law Encourages Investors of Kymera Therapeutics, Inc. to Contact Law Firm
Press releaseSep 2, 4:01 PM ETGlobe Newswire
Kymera Therapeutics to Participate in Upcoming September Investor Conferences
Press releaseSep 1, 7:00 AM ETGlobe Newswire
Kymera Therapeutics Announces Presentations on KT-621, a First-in-Class, Oral STAT6 Degrader, at the European Respiratory Society and European Academy of Dermatology & Venereology Congresses
Press releaseAug 5, 7:00 AM ETGlobe Newswire
Kymera Therapeutics Announces Second Quarter 2026 Financial Results and Provides a Business Update
Press releaseJul 28, 4:01 PM ETGlobe Newswire
Kymera Therapeutics to Report Second Quarter 2026 Financial Results on August 5, 2026
Press releaseJul 27, 8:49 AM ETPRNewswire
Kuehn Law Encourages Investors of Kymera Therapeutics, Inc. to Contact Law Firm
Press releaseJul 16, 11:13 AM ETPRNewswire
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Kymera Therapeutics, Inc. (NASDAQ: KYMR)
Press releaseJul 7, 7:00 AM ETGlobe Newswire
Kymera Therapeutics Appoints Elizabeth Laws, Ph.D., as Senior Vice President, Global Program Team Leader for KT-621, First-in-Class, Oral STAT6 Degrader
NewsJun 25, 1:19 PM ETVandana Singh
Kymera Therapeutics Stock Climbs On Accelerated Timeline For Lead Atopic Dermatitis Program
NewsJun 25, 12:18 PM ETAvi Kapoor
Gold Gains Over 1%; Fed's Preferred Inflation Gauge Surges To 3-Year High
NewsJun 25, 9:55 AM ETAvi Kapoor
Acuity Posts Strong Q3 Results, Joins BlackBerry, MillerKnoll, Qualcomm And Other Big Stocks Moving Higher On Thursday
Press releaseJun 25, 7:00 AM ETGlobe Newswire
Kymera Therapeutics Completes Enrollment in the Phase 2b BROADEN2 Trial of KT-621 in Atopic Dermatitis with Topline Data by Year-end 2026
Press releaseJun 12, 7:00 AM ETGlobe Newswire
Kymera Therapeutics Presents Phase 1 Data in Healthy Japanese Adults for KT-621, a First-in-Class Oral STAT6 Degrader, at the Japanese Dermatological Association Annual Meeting
NewsJun 9, 7:01 AM ET
Kymera Therapeutics Announces First Participant Dosed In First-In-Human Phase 1 Clinical Trial Evaluating KT-485, Oral, Potent And Selective IRAK4 Degrader, In Adult Healthy Volunteers And HS Patients
Press releaseJun 9, 7:00 AM ETGlobe Newswire
Kymera Therapeutics Announces First Participant Dosed in Phase 1 Trial of Oral IRAK4 Degrader, KT-485, and Milestone Achievement Under Sanofi Collaboration
Press releaseJun 8, 7:00 AM ETGlobe Newswire
Kymera Therapeutics Presents New Preclinical Lupus Data for KT-579, First-in-Class, Oral IRF5 Degrader, at EULAR and FOCIS Congresses
Press releaseMay 27, 7:00 AM ETGlobe Newswire
Kymera Therapeutics to Participate in Fireside Chat at the Jefferies Global Healthcare Conference
Press releaseMay 15, 7:00 AM ETGlobe Newswire
Kymera Therapeutics Announces Presentations on KT-621, a First-In-Class, Oral STAT6 Degrader, at the Society for Investigative Dermatology and American Thoracic Society Congresses
Press releaseMay 12, 10:00 AM ETPRNewswire
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Kymera Therapeutics, Inc. (NASDAQ: KYMR)
Press releaseMay 6, 7:00 AM ETGlobe Newswire
Kymera Therapeutics to Participate in Upcoming May Investor Conferences
Press releaseMay 5, 7:00 AM ETGlobe Newswire
Kymera Therapeutics Presents New Preclinical IBD Data for KT-579, a First-in-Class, Oral IRF5 Degrader, at Digestive Disease Week
Press releaseMay 5, 6:37 AM ETBusiness Wire
Jeito Capital Bolsters Its Leadership Team With the Appointment of Elaine Caughey, MBA, as Partner, Business Development and Investor Relations, and Sarah Shackelton, MPA, as Partner, Talent
NewsApr 30, 7:11 AM ET
Earnings Scheduled For April 30, 2026
Press releaseApr 30, 7:00 AM ETGlobe Newswire
Kymera Therapeutics Announces First Quarter 2026 Financial Results and Provides a Business Update
Press releaseApr 23, 7:00 AM ETGlobe Newswire
Kymera Therapeutics to Report First Quarter 2026 Financial Results on April 30, 2026
NewsApr 9, 1:14 PM ETVandana Singh
Gilead Expands Tempus AI Partnership To Boost Oncology Pipeline
NewsMar 31, 9:57 AM ETAvi Kapoor
Apellis Pharmaceuticals, Centessa Pharmaceuticals, Agios Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday
NewsFeb 26, 3:01 PM ET
Analyst Expectations For Kymera Therapeutics's Future
NewsFeb 26, 7:02 AM ET
Kymera Therapeutics Earnings Review: Q4 Summary
Press releaseFeb 26, 7:00 AM ETGlobe Newswire
Kymera Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update
NewsFeb 26, 6:11 AM ET
Earnings Scheduled For February 26, 2026
Press releaseFeb 24, 7:00 AM ETGlobe Newswire
Kymera Therapeutics to Participate in Upcoming March Investor Conferences
Press releaseFeb 19, 7:00 AM ETGlobe Newswire
Kymera Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026
Press releaseFeb 4, 7:00 AM ETGlobe Newswire
Kymera Therapeutics to Participate in Upcoming February Investor Conferences
NewsFeb 3, 9:00 AM ET
Deep Dive Into Kymera Therapeutics Stock: Analyst Perspectives (21 Ratings)
NewsJan 15, 1:00 PM ET
Kymera Therapeutics Stock: A Deep Dive Into Analyst Perspectives (25 Ratings)
Press releaseJan 13, 7:00 AM ETGlobe Newswire
Kymera Therapeutics Outlines Key 2026 Objectives and Strategy to Advance Industry Leading Portfolio of Oral Immunology Programs
Press releaseJan 6, 7:00 AM ETGlobe Newswire
Kymera Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 13
NewsDec 8, 12:33 PM ETAvi Kapoor
Paramount Skydance, Wave Life Sciences, Ocular Therapeutix, Carvana And Other Big Stocks Moving Higher On Monday
NewsDec 8, 9:54 AM ETVandana Singh
Kymera Stock Smashes 52-Week High As New Pill Crushes Eczema Markers
NewsDec 8, 7:34 AM ET
Market-Moving News for December 8th
Press releaseDec 8, 7:00 AM ETGlobe Newswire
Kymera Therapeutics Announces Positive Results from BroADen Phase 1b Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader, in Patients with Moderate to Severe Atopic Dermatitis
Press releaseDec 5, 4:01 PM ETGlobe Newswire
Kymera Therapeutics to Announce KT-621 BroADen Phase 1b Atopic Dermatitis Trial Results on December 8, 2025
Press releaseNov 24, 7:00 AM ETGlobe Newswire
Kymera Therapeutics to Participate in Upcoming December Investor Conferences
NewsNov 5, 6:45 AM ET
10 Analysts Have This To Say About Kymera Therapeutics
Press releaseNov 4, 7:00 AM ETGlobe Newswire
Kymera Therapeutics Announces Third Quarter 2025 Financial Results and Provides a Business Update
Press releaseNov 3, 7:00 AM ETGlobe Newswire
Kymera Therapeutics to Participate in Upcoming November Investor Conferences
NewsSep 16, 9:22 AM ETAvi Kapoor
This Chubb Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.

Latest news

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Kymera Therapeutics, Inc. (NASDAQ: KYMR)

Kuehn Law Encourages Investors of Kymera Therapeutics, Inc. to Contact Law Firm

Kymera Therapeutics to Participate in Upcoming September Investor Conferences

Kymera Therapeutics Announces Presentations on KT-621, a First-in-Class, Oral STAT6 Degrader, at the European Respiratory Society and European Academy of Dermatology & Venereology Congresses

Kymera Therapeutics Announces Second Quarter 2026 Financial Results and Provides a Business Update

Kymera Therapeutics to Report Second Quarter 2026 Financial Results on August 5, 2026

Kuehn Law Encourages Investors of Kymera Therapeutics, Inc. to Contact Law Firm

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Kymera Therapeutics, Inc. (NASDAQ: KYMR)

Kymera Therapeutics Appoints Elizabeth Laws, Ph.D., as Senior Vice President, Global Program Team Leader for KT-621, First-in-Class, Oral STAT6 Degrader

Kymera Therapeutics Stock Climbs On Accelerated Timeline For Lead Atopic Dermatitis Program

Gold Gains Over 1%; Fed's Preferred Inflation Gauge Surges To 3-Year High

Acuity Posts Strong Q3 Results, Joins BlackBerry, MillerKnoll, Qualcomm And Other Big Stocks Moving Higher On Thursday

Kymera Therapeutics Completes Enrollment in the Phase 2b BROADEN2 Trial of KT-621 in Atopic Dermatitis with Topline Data by Year-end 2026

Kymera Therapeutics Presents Phase 1 Data in Healthy Japanese Adults for KT-621, a First-in-Class Oral STAT6 Degrader, at the Japanese Dermatological Association Annual Meeting

Kymera Therapeutics Announces First Participant Dosed In First-In-Human Phase 1 Clinical Trial Evaluating KT-485, Oral, Potent And Selective IRAK4 Degrader, In Adult Healthy Volunteers And HS Patients

Kymera Therapeutics Announces First Participant Dosed in Phase 1 Trial of Oral IRAK4 Degrader, KT-485, and Milestone Achievement Under Sanofi Collaboration

Kymera Therapeutics Presents New Preclinical Lupus Data for KT-579, First-in-Class, Oral IRF5 Degrader, at EULAR and FOCIS Congresses

Kymera Therapeutics to Participate in Fireside Chat at the Jefferies Global Healthcare Conference

Kymera Therapeutics Announces Presentations on KT-621, a First-In-Class, Oral STAT6 Degrader, at the Society for Investigative Dermatology and American Thoracic Society Congresses

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Kymera Therapeutics, Inc. (NASDAQ: KYMR)

Kymera Therapeutics to Participate in Upcoming May Investor Conferences

Kymera Therapeutics Presents New Preclinical IBD Data for KT-579, a First-in-Class, Oral IRF5 Degrader, at Digestive Disease Week

Jeito Capital Bolsters Its Leadership Team With the Appointment of Elaine Caughey, MBA, as Partner, Business Development and Investor Relations, and Sarah Shackelton, MPA, as Partner, Talent

Earnings Scheduled For April 30, 2026

Kymera Therapeutics Announces First Quarter 2026 Financial Results and Provides a Business Update

Kymera Therapeutics to Report First Quarter 2026 Financial Results on April 30, 2026

Gilead Expands Tempus AI Partnership To Boost Oncology Pipeline

Apellis Pharmaceuticals, Centessa Pharmaceuticals, Agios Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday

Analyst Expectations For Kymera Therapeutics's Future

Kymera Therapeutics Earnings Review: Q4 Summary

Kymera Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update

Earnings Scheduled For February 26, 2026

Kymera Therapeutics to Participate in Upcoming March Investor Conferences

Kymera Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026

Kymera Therapeutics to Participate in Upcoming February Investor Conferences

Deep Dive Into Kymera Therapeutics Stock: Analyst Perspectives (21 Ratings)

Kymera Therapeutics Stock: A Deep Dive Into Analyst Perspectives (25 Ratings)

Kymera Therapeutics Outlines Key 2026 Objectives and Strategy to Advance Industry Leading Portfolio of Oral Immunology Programs

Kymera Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 13

Paramount Skydance, Wave Life Sciences, Ocular Therapeutix, Carvana And Other Big Stocks Moving Higher On Monday

Kymera Stock Smashes 52-Week High As New Pill Crushes Eczema Markers

Market-Moving News for December 8th

Kymera Therapeutics Announces Positive Results from BroADen Phase 1b Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader, in Patients with Moderate to Severe Atopic Dermatitis

Kymera Therapeutics to Announce KT-621 BroADen Phase 1b Atopic Dermatitis Trial Results on December 8, 2025

Kymera Therapeutics to Participate in Upcoming December Investor Conferences

10 Analysts Have This To Say About Kymera Therapeutics

Kymera Therapeutics Announces Third Quarter 2025 Financial Results and Provides a Business Update

Kymera Therapeutics to Participate in Upcoming November Investor Conferences

This Chubb Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday